Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | ||
| Iclusig | Ponatinib | Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bosulif (RFA) | Bosutinib | Chronic Myeloid Leukemia | N/A | Complete | ||
| Bosulif | Bosutinib | Chronic Myeloid Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
| Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia (previously untreated) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending |
Last Updated : May 11, 2024